公开(公告)号：US20240360121A1

公开(公告)日：2024-10-31

申请号：US18597265

申请日：2024-03-06

申请人： Board of Regents, The University of Texas System

发明人： Maria Emilia DI FRANCESCO ,  Philip JONES ,  Timothy HEFFERNAN ,  Matthew M. HAMILTON ,  Zhijun KANG ,  Michael J. SOTH ,  Jason P. BURKE ,  Kang LE ,  Christopher Lawrence CARROLL ,  Wylie S. PALMER ,  Richard LEWIS ,  Timothy MCAFOOS ,  Barbara CZAKO ,  Gang LIU ,  Jay THEROFF ,  Zachary HERRERA ,  Anne YAU

IPC分类号： C07D417/14 ,  A61K31/4192 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/497 ,  A61K31/501 ,  A61K45/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D417/06 ,  C07D493/08

CPC分类号： C07D417/14 ,  A61K31/4192 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/497 ,  A61K31/501 ,  A61K45/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D417/06 ,  C07D493/08

摘要： Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I:




Methods of inhibition GLS1 activity in a human or animal subject are also provided.

公开(公告)号：US20240360103A1

公开(公告)日：2024-10-31

申请号：US18573634

申请日：2022-06-30

申请人： Apellis Pharmaceuticals, Inc.

发明人： Johannes Wilhelm Georg Meissner ,  Andrew Simon Cook ,  Mark William Orme

IPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： Among other things, the present disclosure provides technologies for modulating complement activation. In some embodiments, the present disclosure provides compounds that inhibit C3 convertase activity. In some embodiments, the present disclosure provides methods for treating complement-mediated conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for treating conditions, disorders or diseases mediated by C3 convertase.

公开(公告)号：US20240360082A1

公开(公告)日：2024-10-31

申请号：US18291083

申请日：2022-07-22

申请人： NOVARTIS AG

发明人： Graham Charles BLOOMFIELD ,  Matthew James HESSE ,  Richard Yichong HUANG ,  Michael Robert MASER ,  James Clifford SUTTON ,  Benjamin Robert TAFT ,  David Charles TULLY

IPC分类号： C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

CPC分类号： C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

摘要： The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US12121524B2

公开(公告)日：2024-10-22

申请号：US16962441

申请日：2019-01-16

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： Marc Saul Weinberg ,  Diego Sebastian D'Astolfo ,  Sudipta Mahajan

IPC分类号： A61K31/5377 ,  A61K9/00 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/7088 ,  A61K38/46 ,  A61P43/00 ,  C07D413/12 ,  C12N9/22 ,  C12N15/11

CPC分类号： A61K31/5377 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/7088 ,  A61K38/465 ,  A61P43/00 ,  C07D413/12 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2800/80

摘要： The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions, or disorders.

公开(公告)号：US20240336642A1

公开(公告)日：2024-10-10

申请号：US18294441

申请日：2022-08-05

申请人： The General Hospital Corporation ,  The Regents of the University of California

发明人： Klaus van Leyen ,  Yi Zheng ,  Theodore Holman ,  Graham Johnson ,  Robert Jason Herr

IPC分类号： C07F9/653 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  A61P9/10 ,  A61P25/28 ,  C07D263/48 ,  C07D413/12

CPC分类号： C07F9/653 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  A61P9/10 ,  A61P25/28 ,  C07D263/48 ,  C07D413/12

摘要： The present application provides oxazoles-containing compounds, or a pharmaceutically acceptable salt thereof, that are 12/15-LOX inhibitors. Pharmaceutical compositions and methods of using these compounds for treating various conditions wherein 12/15-LOX is implicated (such as stroke) are also provided.

公开(公告)号：US20240336638A1

公开(公告)日：2024-10-10

申请号：US18571763

申请日：2022-06-28

申请人： Guoqin ZHUGE ,  Xiaoqin LI

发明人： Xiaoqin LI ,  Jianfang CHEN

IPC分类号： C07F7/18 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/695 ,  A61P7/02 ,  A61P9/10 ,  C07C69/757 ,  C07D213/16 ,  C07D233/58 ,  C07D233/68 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10

CPC分类号： C07F7/1804 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/695 ,  A61P7/02 ,  A61P9/10 ,  C07C69/757 ,  C07D213/16 ,  C07D233/58 ,  C07D233/68 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10

摘要： An imidazole compound as shown in formula I or a pharmaceutically acceptable salt and an intermediate thereof. The imidazole compound as shown in formula I can significantly inhibit AA-induced platelet aggregation, improves MCAO/R-induced rat cerebral ischemia injury, has excellent metabolic stability, and can improve the distribution of a drug within the brain tissue, such that the pharmacodynamic activity of the imidazole compound in treatment of dyskinesia associated with acute thrombotic cerebral infarction and cerebral infarction is improved.

公开(公告)号：US20240336596A1

公开(公告)日：2024-10-10

申请号：US18567468

申请日：2022-12-06

申请人： NOVOSTAR PHARMACEUTICALS, LTD.

发明人： Bing LI ,  Ke ZHANG ,  WenXing NING ,  XiaoFei ZUO ,  QiongLin HUANG

IPC分类号： C07D403/12 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04

CPC分类号： C07D403/12 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04

摘要： A poly(adenosine diphosphate-ribose)polymerase-7 (PARP7) inhibitor, and the use thereof in selectively inhibiting PARP7 activity or in treating or preventing diseases, disorders or conditions that are regulated by or affected by PARP7 activity or involve PARP7 activity or overexpression therein, wherein the inhibitor comprises a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof.

公开(公告)号：US20240336594A1

公开(公告)日：2024-10-10

申请号：US18576708

申请日：2022-06-24

申请人： BETTA PHARMACEUTICALS CO., LTD

发明人： Bang FU ,  Yinlong LI ,  Wei REN ,  Qichao SHEN ,  Guolong DU ,  Xiaojun ZHOU ,  Yun SUN ,  Yuzhen ZHOU ,  Xiao SUN ,  Weidong CAI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC分类号： C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC分类号： C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

摘要： A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.

公开(公告)号：US20240336574A1

公开(公告)日：2024-10-10

申请号：US18280891

申请日：2022-03-10

申请人： LATIGO BIOTHERAPEUTICS, INC. ,  LIEBER INSTITUTE, INC.

发明人： Robert M. Jones ,  Ashok Bajji ,  Nathaniel Julius Thomas Monck ,  Suzanne J. O'Connor ,  William H. Gardiner ,  Robert James Townsend ,  Andreina Pacheco Pita ,  Michael Brunavs ,  Abdul Kadar Shaikh ,  Jonathan Paul Shine ,  Ian James Wigginton ,  Jonathan Philip Richards ,  Marco Michele Mastandrea ,  Adam James Davenport ,  Bryan Moyer ,  Michael Poslusney ,  James Barrow ,  Richard Edmund Rathmell

IPC分类号： C07D237/24 ,  A61K31/455 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/82 ,  C07D237/26 ,  C07D239/26 ,  C07D241/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

CPC分类号： C07D237/24 ,  A61K31/455 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/82 ,  C07D237/26 ,  C07D239/26 ,  C07D241/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

摘要： The invention provides methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use. The compounds are useful as pharmacological agents to treat a variety of conditions, including various pain states, itch, and cough.

公开(公告)号：US12113177B2

公开(公告)日：2024-10-08

申请号：US18225960

申请日：2023-07-25

申请人： Electrochem Solutions Inc.

发明人： Yufei Wang ,  John S. Miller ,  John Hession ,  Arden P Johnson

IPC分类号： H01M10/0587 ,  A61K31/433 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  C07D213/75 ,  C07D239/42 ,  C07D241/20 ,  C07D285/135 ,  C07D401/04 ,  C07D401/12 ,  C07D417/06 ,  C07D417/08 ,  C07D417/14 ,  H01M4/134 ,  H01M4/36 ,  H01M4/38 ,  H01M4/58 ,  H01M4/62 ,  H01M4/66 ,  H01M10/052 ,  H01M10/0568 ,  H01M10/0569 ,  H01M50/119 ,  H01M50/131 ,  H01M50/138 ,  H01M50/148 ,  H01M50/159 ,  H01M50/186 ,  H01M50/188 ,  H01M50/191 ,  H01M50/466

CPC分类号： H01M10/0587 ,  A61K31/433 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  C07D213/75 ,  C07D239/42 ,  C07D241/20 ,  C07D285/135 ,  C07D401/04 ,  C07D401/12 ,  C07D417/06 ,  C07D417/08 ,  C07D417/14 ,  H01M4/134 ,  H01M4/368 ,  H01M4/382 ,  H01M4/582 ,  H01M4/623 ,  H01M4/625 ,  H01M4/662 ,  H01M10/052 ,  H01M10/0568 ,  H01M10/0569 ,  H01M50/119 ,  H01M50/138 ,  H01M50/1535 ,  H01M50/159 ,  H01M50/186 ,  H01M50/188 ,  H01M50/191 ,  H01M50/466 ,  H01M50/131 ,  H01M2300/0031 ,  Y02A50/30

摘要： A novel wound electrode assembly for a lithium oxyhalide electrochemical cell is described. The electrode assembly comprises an elongate cathode of an electrochemically non-active but electrically conductive carbonaceous material disposed between an inner elongate portion and an outer elongate portion of a unitary lithium anode. That way, lithium faces the entire length of the opposed major sides of the cathode. This inner anode portion/cathode/outer anode portion configuration is rolled into a wound-shaped electrode assembly that is housed inside a cylindrically-shaped casing. A cylindrically-shaped sheet-type spring centered in the electrode assembly presses outwardly to limit axial movement of the electrode assembly. In one embodiment, all the non-active components, except for the cathode current collector, which is nickel, are made of stainless-steel. This provides the cell with a low magnetic signature without adversely affecting the cell's high-rate capability.